Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual MeetingBusiness Wire • 04/21/26
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You MoreThe Motley Fool • 04/04/26
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC FilingThe Motley Fool • 03/04/26
Immunome Reports Full Year 2025 Financial Results and Provides Business UpdateBusiness Wire • 03/03/26
Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With VaregacestatSeeking Alpha • 12/17/25
Why Immunome, A Top 3% Stock, Just Rocketed On Its Rivalry With Merck KGaAInvestors Business Daily • 12/15/25
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid TumorsBusiness Wire • 12/15/25
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid TumorsBusiness Wire • 12/14/25
Immunome Reports Third Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire • 11/06/25
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation ConferenceBusiness Wire • 10/31/25
Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC ResistanceBusiness Wire • 10/23/25
Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains?Zacks Investment Research • 09/25/25
Immunome stock a ‘buy' on ‘rich pipeline' of oncology therapeutics: analystsProactive Investors • 09/23/25